Xiidra
(Lifitegrast)Phase 2Small molecule
Xiidra is one of 86 small molecule programs targeting Allergic Conjunctivitis. It is currently in Phase 2.
3
Indications
17
Total Trials
2
Active Trials
85
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
10
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
219 competitors in Cataract
#DrugCompanyPhaseTrials
1Lotemax
BBausch & Lomb Incorporated
Phase 3
Floxin
WWim Janssens
Phase 3
Isopto Carpine
AAdvanz Pharma
Phase 3
Intranasal Dexmedetomidine
BBaudax Bio
Phase 3
Mapracorat
BayerPhase 3
Tetracaine Hydrochloride
BBausch Health Americas, Inc.
Phase 3
Phenylephrine Hcl
BayerPhase 3
Xiidra
BBausch Health Americas, Inc.
Phase 2
Midalozam
Idorsia Pharmaceuticals Ltd.Phase 3
Zolymbus
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Eye Disease5 trials
Efficacy3 trials
6 more indications
Allergic Conjunctivitis1 trial
Cataract1 trial
Efficacy and Safety1 trial
Prospective1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jul 11, 2016
XIIDRA
NDA NDA208073
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lifitegrast. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Xiidra. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBausch Health Americas, Inc.